Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Pulmonx Corp (LUNG)
Price$1.85Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.5M | $83.8M | $68.7M | $53.7M | $48.4M | $32.7M | $32.6M | $20.0M |
| Gross profit | $67.1M | $62.0M | $50.8M | $39.9M | $35.6M | $21.2M | $22.4M | $12.3M |
| Gross margin | 74.19% | 74.00% | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & development | $19.5M | $17.6M | $18.1M | $15.4M | $13.1M | $7.5M | $6.0M | $7.0M |
| Operating expenses | $120.8M | $119.7M | $112.7M | $98.5M | $82.9M | $53.5M | $40.3M | $27.3M |
| Operating income | −$53.7M | −$57.7M | −$61.9M | −$58.6M | −$47.3M | −$32.3M | −$17.8M | −$15.1M |
| Operating margin | −59.30% | −68.87% | −90.19% | −109.27% | −97.70% | −98.77% | −54.73% | −75.24% |
| EBITDA | −$52.6M | −$56.5M | −$60.4M | −$57.1M | −$46.5M | −$31.9M | −$17.5M | −$14.9M |
| EBITDA margin | −58.08% | −67.44% | −88.00% | −106.48% | −96.05% | −97.55% | −53.81% | −74.25% |
| Net income | −$54.0M | −$56.4M | −$60.8M | −$58.9M | −$48.7M | −$32.2M | −$20.7M | −$18.5M |
| Net profit margin | −59.67% | −67.30% | −88.60% | −109.80% | −100.51% | −98.47% | −63.52% | −92.38% |
| Basic EPSper basic share | -$1.33 | -$1.44 | -$1.60 | -$1.59 | -$1.35 | -$3.16 | -$11.66 | -$11.03 |
| Diluted EPSper diluted share | -$1.33 | -$1.44 | -$1.60 | -$1.59 | -$1.35 | -$3.16 | -$11.66 | -$11.03 |
Owners
Reported shareholders
10.74%of listed shares
PRIMECAP MANAGEMENT CO/CA/4.61M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
PRIMECAP MANAGEMENT CO/CA/ | 10.74%4.61M shares |
MORGAN STANLEY | 6.81%2.92M shares |
Soleus Capital Management, L.P. | 6.49%2.79M shares |
French Glendon E. III | ≈4.88%2.1M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.80%1.63M shares |
Sung Derrick | ≈3.11%1.34M shares |
ExodusPoint Capital Management, LP | 2.85%1.22M shares |
Almitas Capital LLC | 2.48%1.06M shares |
BlackRock, Inc. | 2.05%882.49K shares |
Stonepine Capital Management, LLC | 1.90%815.44K shares |
JANE STREET GROUP, LLC | 1.77%758.23K shares |
BRAIDWELL LP | 1.75%752.54K shares |
AQR CAPITAL MANAGEMENT LLC | 1.73%744.96K shares |
Parkman Healthcare Partners LLC | 1.51%646.56K shares |
Rose Geoffrey Beran | ≈1.07%457.71K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.05%452.68K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.99%425.11K shares |
ADAR1 Capital Management, LLC | 0.94%404.5K shares |
DEUTSCHE BANK AG\ | 0.94%402.32K shares |
Lehman David Aaron | ≈0.88%376.16K shares |
Percentages use 42.95M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | French Glendon E. IIIPresident and CEO | SellCommon Stock | 13.5K | $1.57 | $21.2K | 1.18M |
| Jun 1, 2026Form 4 | Radhakrishnan SrikanthChief Science &Techn. Officer | SellCommon Stock | 6.0K | $1.54 | $9.2K | 331.2K |
| Jun 1, 2026Form 4 | Radhakrishnan SrikanthChief Science &Techn. Officer | SellCommon Stock | 3.7K | $1.54 | $5.7K | 337.2K |
| Jun 1, 2026Form 4 | Radhakrishnan SrikanthChief Science &Techn. Officer | SellCommon Stock | 2.2K | $1.54 | $3.3K | 340.9K |
| Jun 1, 2026Form 4 | Radhakrishnan SrikanthChief Science &Techn. Officer | SellCommon Stock | 2.7K | $1.54 | $4.1K | 343.0K |